BR

BrightPath Biotherapeutics Co., Ltd.

Developing novel cancer immunotherapies, including peptide vaccines and iPS-NKT cell therapies.

4594 | T

Overview

Corporate Details

ISIN(s):
JP3274140007
LEI:
Country:
Japan
Address:
川崎市川崎区殿町三丁目25番22号
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

BrightPath Biotherapeutics is a clinical-stage biopharmaceutical company specializing in the development of novel cancer immunotherapies. The company's pipeline encompasses multiple platforms, including cancer peptide vaccines, immuno-modulators, and advanced cell therapies. A primary focus is its proprietary iPS-NKT platform, a novel allogeneic cell therapy that uses natural killer T-cells (NKT cells) derived from induced pluripotent stem cells (iPSCs) for cancer treatment. This technology enables the large-scale, homogeneous production of NKT cells, which are naturally rare. The company, formerly known as GreenPeptide, also develops peptide vaccines like GRN-1201, which has progressed to clinical trials. Its business model covers drug discovery, research, and early-phase clinical development.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-21 07:30
Registration Form
有価証券届出書(組込方式)
Japanese 241.2 KB
2025-11-14 07:34
Registration Form
確認書
Japanese 8.9 KB
2025-11-14 07:34
Interim Report
半期報告書-第23期(2025/04/01-2026/03/31)
Japanese 198.0 KB
2025-06-20 09:01
Post-Annual General Meeting Information
臨時報告書
Japanese 22.8 KB
2025-06-19 08:36
Registration Form
確認書
Japanese 8.9 KB
2025-06-19 08:32
Governance Information
内部統制報告書-第22期(2024/04/01-2025/03/31)
Japanese 23.4 KB
2025-06-19 08:25
Registration Form
有価証券報告書-第22期(2024/04/01-2025/03/31)
Japanese 933.5 KB
2024-11-08 07:35
Interim Report
確認書
Japanese 9.0 KB
2024-11-08 07:34
Interim Report
半期報告書-第22期(2024/04/01-2025/03/31)
Japanese 224.9 KB
2024-06-21 09:07
Registration Form
訂正有価証券届出書(組込方式)
Japanese 254.0 KB
2024-06-21 08:34
Regulatory News Service
内部統制報告書-第21期(2023/04/01-2024/03/31)
Japanese 23.2 KB
2024-06-21 08:33
Registration Form
確認書
Japanese 9.0 KB
2024-06-21 08:32
Annual Report
有価証券報告書-第21期(2023/04/01-2024/03/31)
Japanese 990.5 KB
2024-06-19 08:00
Registration Form
有価証券届出書(組込方式)
Japanese 513.9 KB
2024-02-09 07:12
Report Publication Announcement
確認書
Japanese 9.1 KB

Automate Your Workflow. Get a real-time feed of all BrightPath Biotherapeutics Co., Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for BrightPath Biotherapeutics Co., Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for BrightPath Biotherapeutics Co., Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

OSE Immunotherapeutics Logo
Develops first-in-class immune therapies for oncology and inflammation, partnering for late-stage.
France
OSE
Oxurion NV Logo
Acquires European pharmaceutical subcontractors to build an integrated healthcare services group.
Belgium
OXUR
PA Co., Ltd Logo
Offers HR solutions like recruitment media, staffing, and childcare to revitalize local communities.
Japan
4766
Passage BIO, Inc. Logo
Developing genetic medicines for severe CNS and neurodegenerative disorders.
United States of America
PASG
PCI Biotech Holding Logo
Biopharma firm evaluating its future after discontinuing its core technology development.
Norway
PCIB
PC İLETİŞİM VE MEDYA HİZMETLERİ SANAYİ TİCARET A.Ş. Logo
Integrated media group providing data-driven advertising and media solutions for global brands.
Türkiye
PCILT
PDS Biotechnology Corp Logo
Developing T-cell activating immunotherapies for cancer and infectious diseases.
United States of America
PDSB
Peers Co.,Ltd. Logo
Accelerating tech adoption with consulting, HR services, and proprietary IT/AI solutions.
Japan
7066
PepGen Inc. Logo
Biotech using an EDO platform to treat genetic neuromuscular & neurological diseases.
United States of America
PEPG
PeptiDream Inc. Logo
Discovers peptide therapeutics via a proprietary platform and markets radiopharmaceuticals.
Japan
4587

Talk to a Data Expert

Have a question? We'll get back to you promptly.